Wir sind mit live! Mehr erfahren
GNCA

Genocea Biosciences, Inc.

Nicht mehr börsennotiert

GNCA wurde am 2. Juni 2022 von der Börse genommen.

 

Profil: Genocea Biosciences Inc is a US-based biopharmaceutical company which is engaged in developing novel vaccines and immunotherapies to address diseases with significant unmet needs. Its product candidate includes GEN-003 which is an immunotherapy for the treatment of genital herpes as well as it owns a pre-clinical immuno-oncology program focused on personalized cancer vaccines. The company focuses on developing vaccines and immunotherapies for unmet needs through its AnTigen Lead Acquisition System, which is used to design vaccines and immunotherapies. Genocea operates its business through the single segment being Developing and Commercializing vaccines.

Mitarbeiter: 74

Nachrichten

Positiv
Neutral
Negativ
Stimmung 3 Monate
Positiv 0 %
Neutral 0 %
Negativ 0 %

Für GNCA liegen uns keine aktuellen Nachrichtenartikel vor.

Kursdiagramme mit Lightweight Charts™ umgesetzt